Brief: Newlink Genetics Announces European Commission Grant Of Conditional Marketing Approval For Ebola Vaccine V920 (Ervebo®)
12/11/2019 14:24
Nov 12 (Reuters) - NewLink Genetics Corp NLNK.O :
* NEWLINK GENETICS ANNOUNCES EUROPEAN COMMISSION GRANT OF
CONDITIONAL MARKETING APPROVAL FOR EBOLA VACCINE V920 (ERVEBO®)
* NEWLINK GENETICS - WITH APPROVAL, EC WILL GRANT
CENTRALIZED
MARKETING AUTHORIZATION FOR VACCINE WITH UNIFIED LABELING VALID
IN 31 EUROPEAN COUNTRIES
Source text for Eikon: ID:nGNX57prWT
Further company coverage: NLNK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)